Roivant Sciences Ltd. - 01 Oct 2026 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ABUS
Reported as of: 01 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Oct 2026, 21:00:29 UTC
Prior SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Keyur Parekh, as Authorized Signatory

Filing notes and source

Key filing fact

Roivant Sciences Ltd. filed Form 4 for Arbutus Biopharma Corp (ABUS) on 05 Oct 2026.

Key facts

This page summarizes Roivant Sciences Ltd.'s Form 4 filing for Arbutus Biopharma Corp (ABUS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Oct 2026, 21:00.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001635088 Primary reporting owner

Roivant Sciences Ltd.

Relationship: Director, 10%+ Owner
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Keyur Parekh, as Authorized Signatory
Signature date: 05 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABUS transaction

Common Shares

Disposed to Issuer

Transaction value
Shares: -8,967,383
Change %: -23%
Price: $5.00^*
Shares after: 29,880,079
Date: 01 Oct 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

The Reporting Person may be deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Matthew Gline (a director of the Issuer who serves as Chief Executive Officer of the Reporting Person and is an employee of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person) and Joseph Bishop (who is an employee of RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person. Lindsay Androski, who also serves on the board of directors of the Issuer, is an employee of RSI and separately serves as President and Chief Executive Officer of the Issuer.